In the BioHarmony Drug Report Database

"Preview" Icon

Ticagrelor

Brilinta, Brilique (ticagrelor) is a small molecule pharmaceutical. Ticagrelor was first approved as Brilinta on 2010-12-03. It has been approved in Europe to treat acute coronary syndrome and peripheral vascular diseases. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target equilibrative nucleoside transporter 1. Brilinta’s patents are valid until 2036-01-27 (FDA).

 

Trade Name

 

Brilique
 

Common Name

 

ticagrelor
 

ChEMBL ID

 

CHEMBL398435
 

Indication

 

acute coronary syndrome, peripheral vascular diseases
 

Drug Class

 

Platelet aggregation inhibitors

Image (chem structure or protein)

Ticagrelor structure rendering